Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

Ulas Darda Bayraktar, Soley Bayraktar, Peter Hosein, Emerson Chen, Leonidas Koniaris, S. Rocha Lima Caio Max, Alberto J. Montero

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

Original languageEnglish (US)
Pages (from-to)1707-1710
Number of pages4
JournalMedical Oncology
Volume29
Issue number3
DOIs
StatePublished - Sep 2012
Externally publishedYes

Fingerprint

docetaxel
Fluorouracil
Cisplatin
Adenocarcinoma
Drug Therapy
Stomach
Disease-Free Survival
Stomach Neoplasms
Survival
Febrile Neutropenia
Neoplasms
Nausea
Vomiting

Keywords

  • Docetaxel
  • Esophageal cancer
  • Gastric cancer
  • Preoperative chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. / Bayraktar, Ulas Darda; Bayraktar, Soley; Hosein, Peter; Chen, Emerson; Koniaris, Leonidas; Caio Max, S. Rocha Lima; Montero, Alberto J.

In: Medical Oncology, Vol. 29, No. 3, 09.2012, p. 1707-1710.

Research output: Contribution to journalArticle

Bayraktar, Ulas Darda ; Bayraktar, Soley ; Hosein, Peter ; Chen, Emerson ; Koniaris, Leonidas ; Caio Max, S. Rocha Lima ; Montero, Alberto J. / Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. In: Medical Oncology. 2012 ; Vol. 29, No. 3. pp. 1707-1710.
@article{9a6ab1d77f2c4aed98d6f400d83de089,
title = "Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma",
abstract = "Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35{\%}) patients achieved partial clinical remission. Ten patients with GEJ cancer (100{\%}) and 13 with gastric cancer (62{\%}) underwent curative surgery (P = 0.023). Seventeen (55{\%}) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95{\%} CI: 22.7-29.5) and 18.8 months (95{\%} CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.",
keywords = "Docetaxel, Esophageal cancer, Gastric cancer, Preoperative chemotherapy",
author = "Bayraktar, {Ulas Darda} and Soley Bayraktar and Peter Hosein and Emerson Chen and Leonidas Koniaris and {Caio Max}, {S. Rocha Lima} and Montero, {Alberto J.}",
year = "2012",
month = "9",
doi = "10.1007/s12032-011-0093-8",
language = "English (US)",
volume = "29",
pages = "1707--1710",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma

AU - Bayraktar, Ulas Darda

AU - Bayraktar, Soley

AU - Hosein, Peter

AU - Chen, Emerson

AU - Koniaris, Leonidas

AU - Caio Max, S. Rocha Lima

AU - Montero, Alberto J.

PY - 2012/9

Y1 - 2012/9

N2 - Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

AB - Perioperative chemotherapy plus surgery improves survival compared to surgery alone in GE junctional (GEJ) and gastric adenocarcinomas. The docetaxel/cisplatin/5-fluorouracil (DCF) combination is superior to CF in patients with metastatic gastric cancer. We retrospectively evaluated the safety and efficacy of preoperative DCF chemotherapy in patients with locally advanced gastric and GEJ cancer. Twenty-one gastric and 10 gastroesophageal junctional (GEJ) cancer patients received 2-3 cycles of preoperative docetaxel 75 mg/m 2 and cisplatin 75 mg/m2 on day 1, 5-FU 750 mg/m 2 (continuous infusion) on days 1-5 every 3 weeks. Clinical response was evaluated by comparing pre- and postchemotherapy CT scans. Overall survival (OS) and progression-free survival (PFS) were calculated from the initiation of chemotherapy. None of the patients achieved complete clinical remission while 11 (35%) patients achieved partial clinical remission. Ten patients with GEJ cancer (100%) and 13 with gastric cancer (62%) underwent curative surgery (P = 0.023). Seventeen (55%) patients experienced grade 3-4 chemotherapy-related adverse events. The most common adverse events were anemia, nausea/vomiting, diarrhea, and febrile neutropenia. At a median follow-up of 17.0 months, median OS and PFS were 26.1 months (95% CI: 22.7-29.5) and 18.8 months (95% CI: 9.9-27.7), respectively. The DCF regimen is active in patients with gastric and GEJ adenocarcinoma in the preoperative setting.

KW - Docetaxel

KW - Esophageal cancer

KW - Gastric cancer

KW - Preoperative chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84872761801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872761801&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-0093-8

DO - 10.1007/s12032-011-0093-8

M3 - Article

C2 - 22033912

AN - SCOPUS:84872761801

VL - 29

SP - 1707

EP - 1710

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

ER -